PharmaStem Patents Confirmed after Reexamination by Patent Office
Complete the form below to unlock access to ALL audio articles.
PharmaStem Therapeutics has announced that the United States Patent and Trademark Office has confirmed all the claims in its pioneering patents regarding umbilical cord blood stem cells.
The Patent Office had previously granted third party requests to reexamine U.S. Patent Nos. 5,004,681, 5,192,553, 6,461,645 and 6,569,427, and has now concluded, after reexamination, that all of the claims are valid.
“Considering the pioneering research of our inventors which eventually led to the creation of the private and public cord blood banking industry, I was always confident that the Patent Office would confirm the validity of our patents and I am gratified that all three senior patent examiners involved in the reexamination reached the same conclusion,” said Nicholas Didier, CEO and President of PharmaStem.
“It is important for our licensees – of which there are over 20 – to know that the patents they have licensed are valid, and can protect them.”
Although the majority of private cord blood banks are licensed under PharmaStem’s patent portfolio, ViaCord (VIAC), Cryo-Cell (CCEL), CBR Systems and CorCell do not have a license to practice the inventions claimed in PharmaStem's patents.
PharmaStem is the successor to Biocyte Corporation, and the pioneer in the development of umbilical cord blood preservation and its therapeutic use. Umbilical cord and placental blood are rich in stem cells that can reconstitute human blood and immune systems.
